MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Alkermes PLC

Cerrado

SectorSalud

30.28 -0.66

Resumen

Variación precio

24h

Actual

Mínimo

29.79

Máximo

30.46

Métricas clave

By Trading Economics

Ingresos

-124M

22M

Ventas

-123M

307M

P/B

Media del Sector

13.723

39.564

BPA

0.291

Margen de beneficio

7.329

Empleados

1,800

EBITDA

-168M

14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+29.81% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1B

4.8B

Apertura anterior

30.94

Cierre anterior

30.28

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

174 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Alkermes PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Charlas de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Ganancias

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Ganancias

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Ganancias

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Ganancias

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Ganancias

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Ganancias

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Ganancias

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Ganancias

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 jul 2025, 15:54 UTC

Ganancias

BASF 2Q Sales Fell 2.1% on Year

11 jul 2025, 15:53 UTC

Ganancias

BASF 2Q Sales EUR15.77B

11 jul 2025, 15:52 UTC

Ganancias

BASF: This Was in Line With Consensus Estimates

11 jul 2025, 15:52 UTC

Ganancias

BASF 2Q Ebitda Before Special Items EUR1.77B

11 jul 2025, 15:49 UTC

Ganancias

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 jul 2025, 15:41 UTC

Charlas de Mercado

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparación entre iguales

Cambio de precio

Alkermes PLC Esperado

Precio Objetivo

By TipRanks

29.81% repunte

Estimación a 12 meses

Media 39.54 USD  29.81%

Máximo 46 USD

Mínimo 30 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

9

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

27.95 / 30.91Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

174 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.